Guggenheim analyst Subbu Nambi lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $73 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: Strong Buy Rating Backed by Strategic Growth Initiatives and Favorable Market Positioning
- Exact Sciences initiated with a Sector Perform at RBC Capital
- Exact Sciences: Promising Growth with Cologuard Plus and New Product Launches
- Exact Sciences price target lowered to $70 from $75 at Piper Sandler
- Exact Sciences price target raised to $73 from $70 at Scotiabank